RESOURCES

Blogs

Insight at the intersection of data science and real-world health

The Talking Room

Demystifying AI, LLMs and machine learning

Use Cases

How teams put the signals to work

Compliance Hub

Data integrity, ethical AI and regulatory standards

DrugVoice

Built to be defensible.

Compliance, ethics, and data integrity are part of the process.

Explore DrugVoice

TMLABS

About us

Where our proprietary models are trained, tested and refined

Articles & scientific publications

Peer-reviewed methodologies and validated outcomes

Latest paper

The New GLP-1 Consumer

Articles & Scientific Publications

Read the Paper

DRUGVOICE

DrugVoice

Measure how your messaging lands and evidence what moved

SEE IT IN ACTION

Bring us a question you can’t answer.

We’ll show you what the conversation already contains, using your therapy area and your audience.

Book a Demo

ABOUT US

About us

Where our proprietary models are trained, tested and refined

ESG

Responsible innovation and ethical data practice

WHO WE ARE

Data scientists who speak pharma.

A team built around one problem: making real-world conversation usable at scale.

Meet the Team
Elevating Healthcare Strategy: Unmasking Game-Changing Insights on GLP-1 & GIP/GLP-1 with Drug-GPT Technology

In collaboration with our partners at Sermo, our Advanced Data Science and Artificial Intelligence solutions played a crucial role in uncovering previously unseen intelligence about GLP-1 and GIP/GLP-1. This report is designed to comprehend challenges, perceptions, attitudes, and usage surrounding GLP-1 and GIP/GLP-1 medications among patients and physicians, reflecting not just our efforts but the collaborative success in providing valuable healthcare intelligence to our partners.

Gain exclusive access to this report and uncover previously unseen insights into the impact of GLP-1 and GIP/GLP-1 drugs in the type 2 diabetes space.

  • Gain insight into how GLP-1 and GIP/GLP-1 drugs have revolutionized the type 2 diabetes space.
  • Explore how physicians and patients alike are talking, thinking, and reacting to GLP-1 and GIP/GLP-1 medications.
  • Deep dive into learnings about specific medications like semaglutide and tirzepatide both from the physician and patient perspective.

Download Now

 

.

Sign Up to Stay Ahead of Message Impact

Discover how Pharma marketeers are finally measuring which messages change HCP behavior. Our newsletter shares evidence-led insights powered by DrugVoice and the Message Resonance Score™ so you can predict and prove message impact—before prescriptions are written.

Subscribe on LinkedIn

Read More

#
$